Diabetes and cancer: clinical implications for integrated metabolic–oncologic care
-
By
-
Vanessa Fuchs-Tarlovsky
-
May 1, 2026
-
Clinical Scorecard: The Intersection of Diabetes and Cancer: Clinical Considerations for Comprehensive Metabolic-Oncologic Management
At a Glance
| Category | Detail |
|---|
| Condition | Diabetes mellitus and cancer coexistence |
| Key Mechanisms | Hyperinsulinemia, insulin resistance, activation of IGF-1 pathway, and metabolic dysregulation |
| Target Population | Individuals with type 2 diabetes and various malignancies |
| Care Setting | Integrated metabolic-oncologic care |
Key Highlights
- Type 2 diabetes correlates with increased risk of hepatocellular, pancreatic, colorectal, endometrial, and breast cancers.
- Cancer treatments can disrupt glycemic control and trigger hyperglycemia.
- Integrated care is essential for managing patients with both diabetes and cancer.
Guideline-Based Recommendations
Diagnosis
- Conduct risk stratification for cancer in patients with type 2 diabetes.
Management
- Implement personalized antidiabetic therapy during cancer treatment.
Monitoring & Follow-up
- Proactive glycemic monitoring is crucial during cancer therapies.
Risks
- Increased infection risk and complications from treatment due to metabolic dysregulation.
Patient & Prescribing Data
Patients with concurrent diabetes and cancer
Personalized therapy selection can enhance treatment tolerance and outcomes.
Clinical Best Practices
- Utilize a multidisciplinary approach for managing patients with both conditions.
- Prioritize organized monitoring for hepatocellular carcinoma in high-risk diabetes patients.
References
